Stock listing
ASX:IMC Immuron Limited Share Price
Home listing (ASX) of Immuron Limited
Follow Immuron Limited into a list and get an email when it puts out news.
Share price · ASX:IMC
$0.037 AUD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.037 – $0.040 AUDNov 20, 2026
- Volume
- 984,625 sharesNov 20, 2026
- Market cap
- $11.95M AUDAt the close on Nov 20, 2026 · price × 322.8M shares outstanding
- 52-week range
- $0.026 – $0.074 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $19,780 AUDMedian day 26,145 shares · 22 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:IMC · Home | $0.037 AUD | 0.000 (0.0%) | 984,625 | $0.040 | $0.040 | $0.037 | $0.037 | Close on Nov 20, 2026 |
| NASDAQ:IMRN | $0.90 USD | +0.05 (+5.9%) | 19,678 | $0.85 | $0.90 | $0.815 | $0.85 | Close on Nov 20, 2026 |
| Frankfurt:ANW | €0.017 EUR | 0.000 (0.0%) | — | €0.017 | €0.017 | €0.017 | €0.017 | Close on Nov 19, 2026 |
| Munich:ANW | €0.027 EUR | 0.000 (0.0%) | — | €0.027 | €0.027 | €0.027 | €0.027 | Close on Nov 20, 2026 |
| Frankfurt:ANWA | €0.66 EUR | -0.085 (-11.4%) | — | €0.72 | €0.72 | €0.66 | €0.745 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:IMC · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.037 | 0.000 | 0.0% | $0.040 | $0.040 | $0.037 | 984,625 | |
| $0.037 | 0.000 | 0.0% | $0.034 | $0.039 | $0.033 | 668,139 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | +0.003 | +8.8% | $0.036 | $0.037 | $0.036 | 29,218 | |
| $0.034 | 0.000 | 0.0% | $0.034 | $0.034 | $0.034 | 0 | |
| $0.034 | 0.000 | 0.0% | $0.034 | $0.034 | $0.034 | 0 | |
| $0.034 | -0.001 | -2.9% | $0.033 | $0.034 | $0.033 | 134,594 | |
| $0.035 | -0.005 | -12.5% | $0.035 | $0.035 | $0.033 | 220,762 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | +0.008 | +25.0% | $0.041 | $0.041 | $0.040 | 2,611 | |
| $0.032 | -0.005 | -13.5% | $0.038 | $0.038 | $0.032 | 125,890 | |
| $0.037 | -0.003 | -7.5% | $0.039 | $0.039 | $0.036 | 591,677 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 23,846 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | +0.006 | +17.6% | $0.036 | $0.040 | $0.036 | 657,877 | |
| $0.034 | 0.000 | 0.0% | $0.034 | $0.034 | $0.034 | 0 | |
| $0.034 | -0.002 | -5.6% | $0.035 | $0.035 | $0.034 | 37,075 | |
| $0.036 | -0.002 | -5.3% | $0.038 | $0.038 | $0.036 | 361,155 | |
| $0.038 | -0.004 | -9.5% | $0.042 | $0.044 | $0.038 | 946,098 | |
| $0.042 | 0.000 | 0.0% | $0.042 | $0.042 | $0.042 | 99,200 | |
| $0.042 | -0.003 | -6.7% | $0.045 | $0.045 | $0.042 | 119,973 | |
| $0.045 | 0.000 | 0.0% | $0.045 | $0.045 | $0.045 | 0 | |
| $0.045 | 0.000 | 0.0% | $0.045 | $0.045 | $0.045 | 0 | |
| $0.045 | +0.007 | +18.4% | $0.040 | $0.045 | $0.040 | 17,447 | |
| $0.038 | -0.002 | -5.0% | $0.038 | $0.038 | $0.038 | 95 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 400,445 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | -0.005 | -11.1% | $0.042 | $0.042 | $0.040 | 227,950 | |
| $0.045 | +0.002 | +4.7% | $0.043 | $0.045 | $0.043 | 562,115 | |
| $0.043 | -0.003 | -6.5% | $0.044 | $0.044 | $0.043 | 901,209 | |
| $0.046 | 0.000 | 0.0% | $0.046 | $0.047 | $0.046 | 30,800 | |
| $0.046 | 0.000 | 0.0% | $0.046 | $0.046 | $0.046 | 1,000 | |
| $0.046 | 0.000 | 0.0% | $0.046 | $0.046 | $0.046 | 0 | |
| $0.046 | +0.001 | +2.2% | $0.044 | $0.046 | $0.044 | 20,675 | |
| $0.045 | -0.003 | -6.3% | $0.047 | $0.047 | $0.044 | 696,276 | |
| $0.048 | +0.002 | +4.3% | $0.046 | $0.051 | $0.046 | 1,211,911 | |
| $0.046 | +0.002 | +4.5% | $0.044 | $0.046 | $0.043 | 156,253 | |
| $0.044 | 0.000 | 0.0% | $0.043 | $0.046 | $0.043 | 1,684,179 | |
| $0.044 | -0.007 | -13.7% | $0.046 | $0.046 | $0.044 | 388,500 | |
| $0.051 | -0.001 | -1.9% | $0.052 | $0.052 | $0.048 | 360,560 | |
| $0.052 | -0.006 | -10.3% | $0.055 | $0.055 | $0.052 | 226,615 | |
| $0.058 | -0.003 | -4.9% | $0.061 | $0.065 | $0.055 | 1,357,524 | |
| $0.061 | +0.003 | +5.2% | $0.058 | $0.064 | $0.058 | 4,234,103 | |
| $0.058 | +0.004 | +7.4% | $0.054 | $0.062 | $0.048 | 3,157,469 | |
| $0.054 | +0.014 | +35.0% | $0.048 | $0.056 | $0.047 | 4,642,398 | |
| $0.040 | +0.003 | +8.1% | $0.041 | $0.044 | $0.040 | 935,152 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 15,251 | |
| $0.037 | -0.002 | -5.1% | $0.038 | $0.038 | $0.037 | 212,178 | |
| $0.039 | +0.001 | +2.6% | $0.039 | $0.039 | $0.039 | 273 | |
| $0.038 | +0.001 | +2.7% | $0.039 | $0.041 | $0.038 | 81,766 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | -0.005 | -11.9% | $0.042 | $0.042 | $0.037 | 26,145 | |
| $0.042 | +0.005 | +13.5% | $0.036 | $0.042 | $0.036 | 145,506 | |
| $0.037 | 0.000 | 0.0% | $0.037 | $0.037 | $0.037 | 0 | |
| $0.037 | +0.003 | +8.8% | $0.037 | $0.037 | $0.037 | 3,774 | |
| $0.034 | -0.001 | -2.9% | $0.034 | $0.034 | $0.034 | 8,300 | |
| $0.035 | -0.002 | -5.4% | $0.035 | $0.035 | $0.035 | 8,300 |
Splits
1 split · ASX:IMC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-40 | Consolidation |
- Ticker
- ASX:IMC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 18, 2026
Results of Annual General Meeting
Latest deck · Nov 18, 2026
Shareholder Meeting (November 2026)
Shareholder meeting · 8 slides
Latest news
Results of Annual General Meeting
Nov 18, 2026
Closed $0.037 (0.0%) on Nov 19, 2026
CEO Address
Nov 17, 2026
Closed $0.037 (0.0%) on Nov 18, 2026
Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Nov 10, 2026
Closed $0.034 (0.0%) on Nov 11, 2026
Immuron Engages LifeSci Capital
Nov 10, 2026
Closed $0.034 (0.0%) on Nov 11, 2026
Emerging Growth Conference Presentation
Oct 28, 2026
Closed $0.04 (+25.0%) on Oct 29, 2026
Immuron Updates At-The-Market Funding Facility
Oct 26, 2026
Closed $0.037 (-7.5%) on Oct 27, 2026
Immuron FY27 Sales Update
Oct 26, 2026
Closed $0.037 (-7.5%) on Oct 27, 2026
CEO to present at Emerging Growth Conference
Oct 21, 2026
Closed $0.04 (0.0%) on Oct 22, 2026
Notice of Annual General Meeting and Proxy Form
Oct 15, 2026
Closed $0.034 (-5.6%) on Oct 16, 2026
Travelan Phase 2 Study Results Published
Oct 12, 2026
Closed $0.042 (0.0%) on Oct 13, 2026
Immuron Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 201 in all · newest Nov 18, 2026 · oldest 2016
- Decks
- 112 decks · latest Nov 18, 2026
Where Immuron Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:IMC · Home listing · This page | ASX | Australia | AUD |
| NASDAQ:IMRN | NASDAQ | United States | USD |
| gettex:ANW | gettex | Germany | EUR |
| Frankfurt:ANW | Frankfurt | Germany | EUR |
| BOATS:IMRN | BOATS | United States | USD |
| Munich:ANW | Munich | Germany | EUR |
| Munich:ANWA | Munich | Germany | EUR |
| Stuttgart:ANW | Stuttgart | Germany | EUR |
| Dusseldorf:ANWA | Dusseldorf | Germany | EUR |
| Frankfurt:ANWA | Frankfurt | Germany | EUR |
| gettex:ANWA | gettex | Germany | EUR |
| Lang & Schwarz:A2DTD8 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2DTD8 | LS Exchange | Germany | EUR |
| Stuttgart:ANWA | Stuttgart | Germany | EUR |
| Tradegate:ANWA | Tradegate | Germany | EUR |
Valuation
EV/sales 0.4× against a median of 5.4×: 2nd lowest of 3 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.93M AUD
- P/E
- Loss
- EV/sales
- 0.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- 64.5%
- Operating margin
- −61.4%
- Net margin
- −49.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immuron Limited · ASX:IMC | US$7.91M | US$1.94M | n/a | 0.4× | n/a | 1.1× | −49.8% | 0.0× | n/a |
| Moleculin Biotech, Inc. · NASDAQ:MBRX | US$8.22M | US$1.04M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.42 |
| IN8bio, Inc. · NASDAQ:INAB | US$8.19M | −US$3.03M | n/a | n/a | n/a | 0.6× | n/a | 0.2× | 1.25 |
| Intensity Therapeutics, Inc. · NASDAQ:INTS | US$8.19M | −US$220,086 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.30 |
| Palatin Technologies, Inc. · AMEX:PTN | US$8.16M | US$4.58M | n/a | 12.7× | n/a | 4.0× | n/a | 0.1× | 0.61 |
| Dare Bioscience, Inc. · NASDAQ:DARE | US$8.01M | −US$2.65M | n/a | −1.9× | n/a | 3.4× | −749.8% | 0.4× | 1.34 |
| Cellectar Biosciences, Inc. · NASDAQ:CLRB | US$8.00M | −US$15.05M | n/a | n/a | n/a | 0.4× | n/a | 0.1× | 1.71 |
| Phio Pharmaceuticals Corp. · NASDAQ:PHIO | US$7.84M | −US$2.77M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.24 |
| Vivesto AB · OMXSTO:VIVE | US$7.77M | US$6.13M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | n/a |
| Annexin Pharmaceuticals AB · OMXSTO:ANNX | US$7.60M | US$6.18M | n/a | n/a | n/a | 6.3× | n/a | 0.0× | n/a |
| Solvonis Therapeutics PLC · LSE:SVNS | US$7.57M | US$6.80M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | n/a |
| Median of the others | US$8.01M | US$408,090 | 5.4× | 1.0× | −749.8% | 0.0× | 1.25 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.29 AUD · Analysts' mean
- Revenue, year to Jun 2027
- 8.64M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Steven Lydeamore | Chief Executive Officer |
| Aaron Laurita | Chief Financial Officer |
| Olga Smejkalova | Company Secretary |
| Flavio Palumbo | Chief Commercial Officer |
| Jerry Kanellos | Chief Scientific Officer |
| Joanne Casey | Research & Development Manager |
Board
| Director | Role |
|---|---|
| Paul Brennan | Chairman |
| Daniel Pollock | Non-Executive Director – LL.B. Dip.L.P. |
| Jeannie Joughin | Non-Executive Director – BSc (Hons), PhD, MAICD |
| Ravi Savarirayan | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −1.5% |
| Q4 2025 | Aug 28, 2025 · Before open | 0.0% |
| Q3 2025 | May 28, 2025 | +14.3% |
| Q2 2025 | Feb 28, 2025 | −6.0% |
| Quarter to Sep 30, 2024 | Oct 16, 2024 | −3.5% |
| Q4 2024 | Aug 30, 2024 | +2.4% |
| Quarter to Mar 31, 2024 | Apr 9, 2024 | +13.6% |
| Q2 2024 | Feb 28, 2024 | +2.9% |
| Quarter to Sep 30, 2023 | Oct 11, 2023 | +5.3% |
| Q4 2023 | Aug 30, 2023 · Before open | +1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Apr 5, 2023 | +14.3% |
| Q2 2023 | Feb 28, 2023 · After close | +2.7% |
| Q1 2023 | Nov 30, 2022 | +5.1% |
| Q4 2022 | Sep 7, 2022 · Before open | 0.0% |
| Q3 2022 | Jun 1, 2022 | +5.0% |
| Q2 2022 | Feb 25, 2022 | +7.1% |
| Q1 2022 | Dec 1, 2021 | −4.2% |
| Q4 2021 | Aug 31, 2021 · After close | 0.0% |
| Q3 2021 | Jun 2, 2021 | 0.0% |
| Q2 2021 | Feb 25, 2021 | −4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2026) | Shareholder meeting | 8 slides | Nov 18, 2026 |
| Shareholder Meeting (November 2026) | Shareholder meeting | 11 slides | Nov 18, 2026 |
| Emerging Growth Conference (October 2026) | Conference | 13 slides | Oct 28, 2026 |
| Emerging Growth Conference 2026 | Conference | 16 slides | Oct 28, 2026 |
| Coffee Microcaps Conference 2026 | Conference | 15 slides | Sep 22, 2026 |
| Coffee Microcaps Conference (September 2026) | Conference | 12 slides | Sep 22, 2026 |
| FY2026 Earnings Presentation | Earnings | 6 slides | Aug 28, 2026 |
| Emerging Growth Conference (August 2026) | Conference | 14 slides | Aug 19, 2026 |
| Emerging Growth Conference (August 2026) | Conference | 11 slides | Aug 19, 2026 |
| TechKnow Invest Roadshow (July 2026) | Conference | 14 slides | Jul 27, 2026 |
Show 50 decks
This page holds 50 of 112 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| At-the-market programme of american Depositary Shares representing ordinary shares Terms changed: up to US$2.01M · H.C. Wainwright & Co., LLC Dealers: H.C. Wainwright & Co., LLC (lead) | Oct 27, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.71M | 7.29M | 4.90M | 1.80M | 765.2K | 145.8K | 2.52M | 2.02M | 1.46M | 1.40M |
| Cost of revenue | 2.74M | 2.52M | 1.57M | 495.6K | 241.7K | 51.1K | 688.8K | 667.4K | 418.7K | 337.5K |
| Gross profit | 4.98M | 4.77M | 3.34M | 1.31M | 523.5K | 94.7K | 1.83M | 1.72M | 1.42M | 1.06M |
| Research and development | 1.93M | 3.60M | 5.38M | 2.59M | 657.7K | 1.37M | 1.18M | 1.04M | 2.26M | 4.63M |
| Selling, general and administrative | 7.72M | 4.48M | 4.52M | 4.22M | 3.52M | 6.09M | 3.10M | 4.95M | 282.2K | 407.8K |
| Operating income | -4.74M | -5.34M | -5.80M | -3.57M | -2.87M | -8.38M | -2.91M | -4.66M | -3.05M | -6.72M |
| Depreciation and amortization | 42.3K | 49.7K | 46.0K | 48.7K | 26.6K | 43.7K | 44.1K | 5.29K | 5.05K | 4.92K |
| EBITDA | -4.69M | -5.29M | -5.76M | -3.52M | -2.84M | -8.34M | -2.86M | -4.65M | -3.04M | -6.72M |
| Interest expense | 14.7K | 7.30K | 7.58K | 9.65K | 6.18K | 13.8K | 21.6K | 21.6K | 24.2K | 89.7K |
| Income before tax | -4.46M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M | -2.93M | -4.66M | -3.07M | -6.80M |
| Income tax | -623.6K | -1.11M | -765.0K | -392.9K | -257.5K | -431.0K | -308.2K | -531.0K | -1.85M | -1.58M |
| Net income | -3.84M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M | -2.93M | -4.66M | -3.07M | -6.80M |
| Earnings per share, basic | -0.01 | -2.26 | -3.04 | -1.66 | -1.25 | -3.79 | -0.02 | -0.03 | -0.02 | -0.08 |
| Earnings per share, diluted | -2.26 | -3.04 | -1.66 | -1.25 | -3.79 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.02M | 2.83M | 11.7M | 17.2M | 22.1M | 25.0M | 3.25M | 5.12M | 4.73M | 3.99M |
| Short-term investments | 3.04M | 0 | 404.1K | 1.83M | 0 | |||||
| Receivables | 1.25M | 1.93M | 1.39M | 417.4K | 662.9K | 334.7K | 327.7K | 968.9K | 1.68M | 1.77M |
| Inventory | 2.27M | 1.77M | 1.58M | 840.0K | 326.6K | 292.5K | 797.7K | 544.3K | 497.9K | 2.34M |
| Current assets | 12.8M | 10.0M | 14.7M | 20.4M | 23.7M | 25.8M | 4.41M | 6.68M | 7.05M | 8.27M |
| Property, plant and equipment | 114.0K | 154.3K | 200.1K | 226.7K | 33.7K | 70.8K | 17.1K | 20.4K | 18.8K | |
| Total assets | 13.0M | 10.1M | 15.5M | 22.0M | 24.9M | 27.1M | 6.20M | 8.56M | 9.24M | 8.29M |
| Accounts payable | 1.35M | 1.53M | 2.14M | 1.19M | 1.16M | 758.5K | 384.4K | 1.09M | 689.3K | 1.29M |
| Current liabilities | 1.79M | 1.97M | 2.70M | 2.22M | 1.50M | 1.12M | 516.4K | 1.20M | 803.3K | 1.71M |
| Total debt | 117.1K | 173.5K | 189.1K | 209.8K | 20.5K | 61.1K | 42.2K | 365.9K | ||
| Total liabilities | 1.99M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M | 558.3K | 1.21M | 803.3K | 1.71M |
| Shareholders' equity | 11.0M | 8.07M | 12.7M | 19.6M | 23.2M | 25.9M | 5.64M | 7.35M | 8.44M | 6.57M |
| Shares outstanding | 297.6M | 230.9M | 227.9M | 18 | 227.6M | 221.1M | 176.4M | 144.7M | 130.0M | 80.1M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.07M | -6.14M | -5.88M | -2.60M | -3.15M | -4.08M | -3.15M | -1.80M | -3.50M | -6.94M |
| Capital spending | -4.75K | -2 | -195 | -7.74K | -10.0K | -6.63K | -864 | -2.05K | -6.59K | -5.70K |
| Free cash flow | -3.07M | -6.14M | -5.88M | -2.60M | -3.16M | -4.09M | -3.15M | -1.80M | -3.51M | -6.95M |
| Cash from investing | 3.03M | -2.90M | 327.6K | -2.62M | 11.7K | 2.57K | -864 | -2.01K | -5.32K | 2.69K |
| Cash from financing | 6.49M | 199.7K | 829 | -44.7K | -42.4K | 26.5M | 1.16M | 2.07M | 4.35M | 8.60M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Share buybacks | -121.8K | 396.8K | 24.0K | 0 | 0 | 29.3M | 1.96M | 2.89M | 5.47M | 12.5M |
| Change in cash | 6.19M | -8.84M | -5.55M | -5.26M | -3.18M | 22.4M | -1.99M | 268.6K | 839.1K | 1.66M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| Results of Annual General Meeting | Nov 18, 2026 | Meeting outcome | ASX |
| CEO Address | Nov 17, 2026 | Annual report | ASX |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| Immuron Engages LifeSci Capital | Nov 10, 2026 | Other filings | ASX |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| Emerging Growth Conference Presentation | Oct 28, 2026 | Other filings | ASX |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
| Immuron Updates At-The-Market Funding Facility | Oct 26, 2026 | Financing | ASX |
| Immuron FY27 Sales Update | Oct 26, 2026 | Results | ASX |
Show 200 filings
This page holds 200 of 604 filings. Open Filings
Cap table
Built by 6ix from Immuron Limited’s releases
- Common shares
- 322,848,081
- Fully diluted
- 322,848,081
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 322,848,081 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 322,848,081 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aaron Laurita Other companies: Radiopharm Theranostics Limited (Chief Financial Officer · Since at least Mar 18, 2026) | Chief Financial Officer · Since at least Feb 9, 2026 |
| Daniel Pollock | Non-Executive Director – LL.B. Dip.L.P. · Since at least Mar 18, 2026 |
| Flavio Palumbo | Chief Commercial Officer · Since at least Mar 18, 2026 |
| Jeannette Anne Joughin | Director · Since at least Mar 18, 2026 |
| Jeannie Joughin | Non-Executive Director – BSc (Hons), PhD, MAICD · Since at least Nov 5, 2026 |
| Jerry Kanellos | Chief Scientific Officer · Since at least Mar 18, 2026 |
| Jerry Kanellos | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Joanne Casey | Research & Development Manager · Since at least Nov 5, 2026 |
| Olga Smejkalova | Company Secretary · Since at least Nov 5, 2026 |
| Paul Brennan | Chairman · Since at least Mar 18, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Ravi Savarirayan | Non-Executive Director · Since at least Mar 18, 2026 |
| Steven George Lydeamore | Chief Executive Officer · Since at least Mar 18, 2026 |
| Steven Lydeamore | Chief Executive Officer · Since at least Oct 28, 2026 |
Log in to ask 6ix AI your own questions about Immuron Limited.